EXEL Quote, Financials, Valuation and Earnings

Aldeyra Therapeutics, Inc. has a net margin of 32.38% compared to Exelixis, Inc.'s net margin of --. Exelixis, Inc.'s return on equity of 31.26% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.

Exelixis, Inc. has a consensus price target of $45.17, signalling downside risk potential of -2.22%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 132.37%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Exelixis, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Exelixis, Inc..

Exelixis, Inc. has a beta of 0.398, which suggesting that the stock is 60.171% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.858, suggesting its less volatile than the S&P 500 by 14.241%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.

Exelixis, Inc. quarterly revenues are $597.8M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Exelixis, Inc.'s net income of $193.6M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Exelixis, Inc.'s price-to-earnings ratio is 19.45x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.78x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 32.38% compared to Exelixis, Inc.'s net margin of 33.68%. Exelixis, Inc.'s return on equity of 31.26% beat Merck & Co., Inc.'s return on equity of 39.63%.

Exelixis, Inc. has a consensus price target of $45.17, signalling downside risk potential of -2.22%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.62 which suggests that it could grow by 1.86%. Given that Merck & Co., Inc. has higher upside potential than Exelixis, Inc., analysts believe Merck & Co., Inc. is more attractive than Exelixis, Inc..

Exelixis, Inc. has a beta of 0.398, which suggesting that the stock is 60.171% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.02% to investors and pays a quarterly dividend of $0.85 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Exelixis, Inc. quarterly revenues are $597.8M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Exelixis, Inc.'s net income of $193.6M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Exelixis, Inc.'s price-to-earnings ratio is 19.45x while Merck & Co., Inc.'s PE ratio is 14.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.78x versus 4.28x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Neurocrine Biosciences, Inc. has a net margin of 32.38% compared to Exelixis, Inc.'s net margin of 26.36%. Exelixis, Inc.'s return on equity of 31.26% beat Neurocrine Biosciences, Inc.'s return on equity of 15.8%.

Exelixis, Inc. has a consensus price target of $45.17, signalling downside risk potential of -2.22%. On the other hand Neurocrine Biosciences, Inc. has an analysts' consensus of $179.70 which suggests that it could grow by 27.79%. Given that Neurocrine Biosciences, Inc. has higher upside potential than Exelixis, Inc., analysts believe Neurocrine Biosciences, Inc. is more attractive than Exelixis, Inc..

Exelixis, Inc. has a beta of 0.398, which suggesting that the stock is 60.171% less volatile than S&P 500. In comparison Neurocrine Biosciences, Inc. has a beta of 0.283, suggesting its less volatile than the S&P 500 by 71.678%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurocrine Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Neurocrine Biosciences, Inc. pays out -- of its earnings as a dividend.

Exelixis, Inc. quarterly revenues are $597.8M, which are smaller than Neurocrine Biosciences, Inc. quarterly revenues of $794.9M. Exelixis, Inc.'s net income of $193.6M is lower than Neurocrine Biosciences, Inc.'s net income of $209.5M. Notably, Exelixis, Inc.'s price-to-earnings ratio is 19.45x while Neurocrine Biosciences, Inc.'s PE ratio is 33.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.78x versus 5.36x for Neurocrine Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 32.38% compared to Exelixis, Inc.'s net margin of -40.15%. Exelixis, Inc.'s return on equity of 31.26% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Exelixis, Inc. has a consensus price target of $45.17, signalling downside risk potential of -2.22%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.13 which suggests that it could grow by 53.69%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Exelixis, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Exelixis, Inc..

Exelixis, Inc. has a beta of 0.398, which suggesting that the stock is 60.171% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Exelixis, Inc. quarterly revenues are $597.8M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Exelixis, Inc.'s net income of $193.6M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Exelixis, Inc.'s price-to-earnings ratio is 19.45x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.78x versus 2.37x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.